Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Calidi Biotherapeutics, Inc. Common Stock (NY:CLDI)

0.4400 -0.0230 (-4.97%)
Official Closing Price Updated: 8:00 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 156,844
Open 0.4500
Bid (Size) 0.4200 (5)
Ask (Size) 0.4700 (10)
Prev. Close 0.4630
Today's Range 0.4101 - 0.4799
52wk Range 0.3500 - 4.900
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Portuguese Researchers Make Progress in Developing Immunotherapy Targeting Colorectal Cancer
Via Investor Brand Network

Performance

YTD
-62.7%
-62.7%
1 Month
-39.4%
-39.4%
3 Month
-47.3%
-47.3%
6 Month
-61.1%
-61.1%
1 Year
-71.8%
-71.8%

More News

Read More
Portuguese Researchers Make Progress in Developing Immunotherapy Targeting Colorectal Cancer
Via Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Clearance to Begin Trials for CLD-201 in Solid Tumors
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Cancer Platforms, Reports Narrowed Loss for Q4 2024
Via Investor Brand Network
Study Explains Why Melanoma, Other Cancers Evade and Resist Immunotherapy
Via Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs
Via Investor Brand Network
Natural Killer Cells That are Genetically Modified Show Potential in Cancer Immunotherapy
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces $3.9 Million Registered Direct Offering and Private Placement
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Encouraging Progress in Brain Cancer Trial with City of Hope
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments
Via Investor Brand Network
New Study Shows ‘Viral Mimicry’ Could Transform Glioblastoma Treatment
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) Novel Therapies Show Promise Against Aggressive Cancers
Via Investor Brand Network
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Stands at the Forefront of Integrating New Oncology Therapies
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform
Via Investor Brand Network
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) and OS Therapies (NYSE American: OSTX) to Appear on RedChip’s Bloomberg TV Show
Via Investor Brand Network
Exposures Product Safety
Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Launches “CLD-101” Trial for High-Grade Glioma at Northwestern
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focused on Advancing Stem Cell-Based Research Amid Rising Cancer Concerns
Via Investor Brand Network
Which stocks are moving after the closing bell on Wednesday?
Via Chartmill

Frequently Asked Questions

Is Calidi Biotherapeutics, Inc. Common Stock publicly traded?
Yes, Calidi Biotherapeutics, Inc. Common Stock is publicly traded.
What exchange does Calidi Biotherapeutics, Inc. Common Stock trade on?
Calidi Biotherapeutics, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Calidi Biotherapeutics, Inc. Common Stock?
The ticker symbol for Calidi Biotherapeutics, Inc. Common Stock is CLDI on the New York Stock Exchange
What is the current price of Calidi Biotherapeutics, Inc. Common Stock?
The current price of Calidi Biotherapeutics, Inc. Common Stock is 0.4400
When was Calidi Biotherapeutics, Inc. Common Stock last traded?
The last trade of Calidi Biotherapeutics, Inc. Common Stock was at 04/21/25 08:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.